In rats, a 10% or 25% ethanolic extract of Artemisia absinthium (wormwood) reduced the severity of certain withdrawal symptoms—such as writhing, body dragging, teeth chattering, and diarrhea—induced by MDMA and naloxone. Lower concentrations (5%) and the MDMA-only group were not well tolerated. The extract's anti-inflammatory, antioxidant, and neuroprotective properties may underlie these effects, but further research is needed to optimize dosing for managing addiction withdrawal.
Buprenorphine therapy is a primary treatment for opioid addiction and chronic pain, but a one-size-fits-all approach is no longer adequate. This review compares two dosing strategies: microdosing, which uses minimal doses to reduce dependence and side effects, and macrodosing, which uses higher doses that are effective but raise concerns about misuse and overdose. Tailoring therapy to individual patient needs is essential for addressing contemporary healthcare challenges in pain management and opioid addiction.